Achillion Pharmaceuticals, Inc.
If you purchased Achillion Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
ACHILLION MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ACHILLION PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – ACHN
October 16, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) to Alexion Pharmaceuticals, Inc. (“Alexion”) is fair to Achillion shareholders. On behalf of Achillion shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Under the terms of the agreement, Achillion shareholders will receive an initial consideration of $6.30 per share of Achillion common stock. According to Achillion, the transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights, which would be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods.
The Achillion merger investigation concerns whether Achillion and its Board of Directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Achillion shareholders; (2) determine whether Alexion is underpaying for Achillion; and (3) disclose all material information necessary for Achillion shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.